Investment Q&A

Q: CVS has dropped significantly in recent months, and I'd appreciate it if you could explain what has been going on. What future do you see for CVS?

Q: Do you have an opinion on this company? Is it pure speculation at this point?

Q: I have held Novartis for a few years and still show a profit of ~33%. However it has dropped significantly in the last 18 months. In the pharma space, I also hold Knight Therapeutic (GUD) and Johnson & Johnson (JNJ). I wonder if Novartis is still worth keeping or should I consider switching to something else (or increasing my holding in J&J or GUD). It represents ~1% of my portfolio which is well diversified but light on pharma. Although not your primary field of expertise, I would still appreciate any light you could shed on the company. Thank you for your valuable insights.

Q: How do you interpret the announcement the company made today on one of their products?

Is this just a pop or a longer term effect?

Thanks

Sheldon

Q: I'm considering buying some GILD.My portfolio is all CDN stocks so it should benefit from some diversification and I feel US stocks may gain some strength under Trump.Obviously GILD is very cheap which reminds me a little of Concordia when I bought what I thought was an undervalued health care stock only to watch it nose dive.I also noticed a few reputable investment firms loading up over the last 2 months.My other choice was to buy PBH which is a great company but very expensive.What are your thoughts on a very cheap GILD which adds some diversification vs a fairly expensive PBH which is currently performing much better? I find i'm more of a GARP than a value investor but I appreciate getting a great stock on sale.

Q: Could you please provide an updated opinion on Merus. Stock is up 5% today. Do you consider this a buy or am I best to stick with GUD and SIS and forget about MSL.

Q: Would appreciate your review of 3rd quarter results and the company announcements.
John

Q: is the rise in the stock price the last couple of days warranted by news facts and could it go back down as fast as it came up

Q: With the drop of SIS, with no position. Is this time to add a full position?

Q: Good morning, I need to increase my healthcare to 5%. Only holding now is GUD which is 1.7%. Considering going back into PLI and another name or what do you suggest? Have spare $US if that would be better.
Thanks for the continuing helpful advice..

Ted

Q: In many of the ETFs that track US healthcare, some of the sub-sectors took a hit yesterday while others outperformed. Is it too early to tell what this portends? Given the new U.S. admin, I’d be grateful if you could share your thoughts on your favourites in this space, especially among the broadly diversified ones. Thanks very much.

Q: Hi, Any comments/significance of following news.

Savaria President and CFO Exercise their Warrants
10:19 EST Wednesday, November 09, 2016
LAVAL, QUEBEC--(Marketwired - Nov. 9, 2016) - Savaria Corporation (TSX:SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, announces that a company wholly owned by Marcel Bourassa, President and Chief Executive Officer of Savaria and Jean-Marie Bourassa, Chief Financial Officer of Savaria, has exercised 500,000 warrants to acquire an equivalent number of common shares of Savaria at a price of $4.25 per share. Savaria will receive gross proceeds of $2,125,000 from the issuance of the shares.

The warrants were issued in connection with a bought deal private placement completed on April 15, 2014, and were set to expire on April 15, 2017. As of today, 1,004,750 warrants have been exercised, representing 35% of the 2,875,000 warrants issued in connection with the 2014 private placement.

Savaria now has 36,350,197 common shares issued and outstanding. Combined, Marcel and Jean-Marie Bourassa hold, directly and indirectly, 14,874,022 shares, representing 40.9% of the Corporation's issued and outstanding common shares.

Q: Please name a couple of pharma stocks that could rally with the election results. Thanks!

Q: I got into CRH after reading your comments on it (and other reports on the website), and added more before the earnings report, so kudos to you. Now that the stock has moved up so much, however, I am trying to figure out how one can tell if it has moved up too much, too fast. My question, then, is how do you tell when it is overvalued?

I know this is a difficult question for a stock that is small, with high growth, and depends on acquisitions, but nonetheless, one has to make decisions and I am struggling with it. I only have a half position in this, so its not a huge risk for me, and I love to watch the daily moves and growth in cash flow.......but I don't want to be married to any stock beyond all reason. Your thoughts would be appreciated.

Q: CRH seems to be moving up on good volume. Are you aware of any news that might be causing this.

Q: I use the word gambling in this question as this is what it is-so would Valeant at this point be a better choice than Concordia if one wanted to gamble on a bounce.

Q: Can you provide a schedule for the various debts of CXR.
Presume it's unrealistic at this time to guess at future earnings for next 2 years.
Thank You
Joe

Q: I understand there are rumours in the market place that Knight and Endo are in discussions for the sale of their Paladin Labs interest...would you be able to provide a little color as to the size of the unit...ie...Sales / Earnings and also a multiple you feel GUD could pay that the market would like..please and thank you

Q: knight is by far my biggest holding, watching it drop from 9.80 to 8.50 this morning was painful, I kept buying all the way down.
and then 20 minutes ago the news comes that knight is in negotiations to buy back paladin at a much lower price,whats is your take on this as the stock rockets higher. dave

Q: This stock has basically declined since inception. The current dividend is just over 9%. Is this sustainable for 2017 and onward? What is your opinion of the stock?